GH1 and adenoma: Prolactinomas comprise 40% to 57% of all adenomas, followed by nonfunctioning adenomas (46% to 74%), growth hormone–secreting adenomas (11% to 13%), and adrenocorticotropic hormone (ACTH)–secreting adenomas (1% to 2%).16 As prolactinomas were not included in this patient series majority of patients had non secretory adenoma 52 (82.5%) presenting with symptoms of mass effect or hypopituitarism.